CL2021002212A1 - Tratamiento de lesión renal - Google Patents
Tratamiento de lesión renalInfo
- Publication number
- CL2021002212A1 CL2021002212A1 CL2021002212A CL2021002212A CL2021002212A1 CL 2021002212 A1 CL2021002212 A1 CL 2021002212A1 CL 2021002212 A CL2021002212 A CL 2021002212A CL 2021002212 A CL2021002212 A CL 2021002212A CL 2021002212 A1 CL2021002212 A1 CL 2021002212A1
- Authority
- CL
- Chile
- Prior art keywords
- kidney injury
- treatment
- methods
- agents
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1902419.9A GB201902419D0 (en) | 2019-02-22 | 2019-02-22 | Treatment of kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002212A1 true CL2021002212A1 (es) | 2022-04-18 |
Family
ID=65998854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002212A CL2021002212A1 (es) | 2019-02-22 | 2021-08-19 | Tratamiento de lesión renal |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11339216B2 (enExample) |
| EP (1) | EP3927742A1 (enExample) |
| JP (1) | JP7638215B2 (enExample) |
| KR (1) | KR20210144708A (enExample) |
| CN (1) | CN113748131A (enExample) |
| AU (1) | AU2020224346A1 (enExample) |
| BR (1) | BR112021016613A2 (enExample) |
| CA (1) | CA3130027A1 (enExample) |
| CL (1) | CL2021002212A1 (enExample) |
| EA (1) | EA202191988A1 (enExample) |
| GB (1) | GB201902419D0 (enExample) |
| MX (1) | MX2021010025A (enExample) |
| PH (1) | PH12021552024A1 (enExample) |
| TW (1) | TWI874359B (enExample) |
| WO (1) | WO2020169783A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
| TWI907583B (zh) * | 2020-12-11 | 2025-12-11 | 大陸商江蘇恒瑞醫藥股份有限公司 | Jak抑制劑在腎臟疾病中的應用 |
| WO2023023473A1 (en) * | 2021-08-16 | 2023-02-23 | Sierra Oncology, Inc. | Methods of using momelotinib to treat chronic kidney disease |
| CN115068442A (zh) * | 2021-09-13 | 2022-09-20 | 荣灿生物医药技术(上海)有限公司 | 核酸的纳米颗粒组合物、其制备方法和用途 |
| CN113960302B (zh) * | 2021-09-29 | 2024-04-23 | 中国人民解放军军事科学院军事医学研究院 | 一种基于高内涵技术的肾毒性检测方法及其应用 |
| US20230145258A1 (en) * | 2021-11-11 | 2023-05-11 | Laboratory Corporation Of America Holdings | Predicting a Diagnostic Test Result From Patient Laboratory Testing History |
| US20250082608A1 (en) * | 2021-12-16 | 2025-03-13 | Singapore Health Services Pte Ltd. | Treatment and prevention of glomerular disease |
| CN114982708A (zh) * | 2022-05-11 | 2022-09-02 | 成都医学院第一附属医院 | 一种小鼠造影剂肾病模型及其构建方法 |
| CN119233818A (zh) | 2022-05-20 | 2024-12-31 | 学校法人藤田学园 | 用于肾损伤的治疗方法或预防方法中的药物组合物和包含该药物组合物的联用药、以及ccbl1抑制剂 |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| CN120787238A (zh) | 2023-01-06 | 2025-10-14 | 拉森医疗公司 | 用于治疗甲状腺眼病的抗IL-11Rα抗体 |
| CN119925593B (zh) * | 2023-06-05 | 2025-11-25 | 北京东方百泰生物科技股份有限公司 | 一种抗il-11单克隆抗体的药物制剂 |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| WO2025238135A2 (en) | 2024-05-17 | 2025-11-20 | UCB Biopharma SRL | Antibody with binding specificity for il-11 |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
| CN119548507A (zh) * | 2024-11-12 | 2025-03-04 | 安徽医科大学 | 5-甲基四氢叶酸在制备治疗肾脏纤维化的药物中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| ES2093562B1 (es) | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
| US6649192B2 (en) | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2237915A1 (en) | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| MX352516B (es) | 2006-07-05 | 2017-04-06 | Fibrotech Therapeutics Pty Ltd | Compuestos terapeuticos. |
| US8182814B2 (en) | 2007-10-26 | 2012-05-22 | Csl Limited | Methods of treating inflammatory airway conditions by inhibition of IL-11 activity |
| JP5330398B2 (ja) | 2007-10-26 | 2013-10-30 | シーエスエル、リミテッド | サイトカインムテイン |
| US8518888B2 (en) | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| CN117843785A (zh) | 2013-02-07 | 2024-04-09 | Csl有限公司 | Il-11r结合蛋白及其应用 |
| GB201522186D0 (en) * | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| CN108210909A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗脂质肾损伤的药物及其用途 |
| CN108210894A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗病理性肾组织损伤的药物及其用途 |
| US20180186871A1 (en) * | 2016-12-16 | 2018-07-05 | Singapore Health Services Pte Ltd. | Il-11 antibodies |
| GB201621431D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore The | Decoy cytokine receptor |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| US20200031920A1 (en) | 2017-04-04 | 2020-01-30 | The George Washington University | Combination Therapy for Treating Cancer |
| GB201716733D0 (en) * | 2017-10-12 | 2017-11-29 | Nat Univ Singapore | Treatment of SMC mediated disease |
| GB201806918D0 (en) | 2018-04-27 | 2018-06-13 | Enleofen Bio Pte Ltd | Combination treatment for eye fibrosis |
| GB201809700D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201809699D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
-
2019
- 2019-02-22 GB GBGB1902419.9A patent/GB201902419D0/en not_active Ceased
-
2020
- 2020-02-21 BR BR112021016613A patent/BR112021016613A2/pt unknown
- 2020-02-21 US US16/798,101 patent/US11339216B2/en active Active
- 2020-02-21 JP JP2021549211A patent/JP7638215B2/ja active Active
- 2020-02-21 EA EA202191988A patent/EA202191988A1/ru unknown
- 2020-02-21 CA CA3130027A patent/CA3130027A1/en active Pending
- 2020-02-21 MX MX2021010025A patent/MX2021010025A/es unknown
- 2020-02-21 AU AU2020224346A patent/AU2020224346A1/en active Pending
- 2020-02-21 KR KR1020217030110A patent/KR20210144708A/ko active Pending
- 2020-02-21 CN CN202080016183.XA patent/CN113748131A/zh active Pending
- 2020-02-21 PH PH1/2021/552024A patent/PH12021552024A1/en unknown
- 2020-02-21 EP EP20707590.4A patent/EP3927742A1/en active Pending
- 2020-02-21 TW TW109105725A patent/TWI874359B/zh active
- 2020-02-21 WO PCT/EP2020/054580 patent/WO2020169783A1/en not_active Ceased
-
2021
- 2021-08-19 CL CL2021002212A patent/CL2021002212A1/es unknown
-
2022
- 2022-05-23 US US17/751,117 patent/US12234284B2/en active Active
-
2025
- 2025-01-17 US US19/028,642 patent/US20250270310A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201902419D0 (en) | 2019-04-10 |
| AU2020224346A1 (en) | 2021-10-07 |
| US20250270310A1 (en) | 2025-08-28 |
| CA3130027A1 (en) | 2020-08-27 |
| US11339216B2 (en) | 2022-05-24 |
| JP2022521591A (ja) | 2022-04-11 |
| KR20210144708A (ko) | 2021-11-30 |
| CN113748131A (zh) | 2021-12-03 |
| BR112021016613A2 (pt) | 2021-11-03 |
| TWI874359B (zh) | 2025-03-01 |
| TW202037605A (zh) | 2020-10-16 |
| US12234284B2 (en) | 2025-02-25 |
| MX2021010025A (es) | 2021-11-12 |
| EP3927742A1 (en) | 2021-12-29 |
| EA202191988A1 (ru) | 2021-12-08 |
| US20200270340A1 (en) | 2020-08-27 |
| US20220403017A1 (en) | 2022-12-22 |
| PH12021552024A1 (en) | 2022-08-22 |
| TW202521575A (zh) | 2025-06-01 |
| WO2020169783A1 (en) | 2020-08-27 |
| JP7638215B2 (ja) | 2025-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002212A1 (es) | Tratamiento de lesión renal | |
| CL2021002878A1 (es) | Tratamiento y prevención de enfermedades metabólicas | |
| CL2021001903A1 (es) | Tratamiento de la hepatotoxicidad | |
| SA521422031B1 (ar) | مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين | |
| EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
| CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| MX2022005216A (es) | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). | |
| CL2020002018A1 (es) | Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582) | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| EA202092590A1 (ru) | Пиридазиноны в качестве ингибиторов parp7 | |
| BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| MX2025012087A (es) | Piridazinonas y metodos de uso de estas | |
| JOP20210323A1 (ar) | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 | |
| MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
| MA43335B1 (fr) | Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| MX2018011419A (es) | Moduladores de receptores estrogénicos. | |
| EA202191122A1 (ru) | СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| MX2022002337A (es) | Polipéptidos de tff2 modificados. | |
| WO2018175749A3 (en) | LRP1 BINDING AGENTS AND USES THEREOF | |
| BR112018009745A2 (pt) | compostos heterocíclicos para o tratamento de doença | |
| EA201991395A1 (ru) | Новые композиции для лечения суставных нарушений |